It was in with the new and out with the old Jan. 3 as the gavel came down on the first session of the 119th U.S. Congress.

Balt Group SAS recently secured €355 million (US$365 million) in funding to refinance its debt, invest in research and accelerate its growth. The French-based provider of interventional neuroradiology ...

Already hot for years, antibody-drug conjugates (ADCs) continued to hold charm for the industry, sparking a number of sizable ...

The device industry is extraordinarily dependent on administrative activity where Medicare coverage is concerned, and this ...

Roche Holding AG kicked off the new year (again) with a potential $1 billion deal, including $80 million up front, for ...

The Asia Pacific med-tech market is projected to reach $140 billion in 2025 in value, growing roughly 5% per year, driven ...

Zhongzhi Pharmaceutical Holdings Ltd. made a $3 million investment in a series A financing round of stem cell therapy developer Gabaeron Inc. Dec. 21, expected to help propel Gabaeron’s preclinical ...

Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of ...

Major depressive disorder (MDD) notched another late-stage failure in the form of Neumora Therapeutics Inc.’s data from the phase III Koastal-1 study, the first of three replicant trials in the ...

The U.K. government will unveil its 10-year health plan to transform the national health service (NHS) in the coming months. At the center of this transformation is expected to be the adoption of ...

A recent study by researchers from Fudan University and Tau Cambridge Ltd. explored a novel therapeutic strategy that combines targeting CD47 with ANGPTL3, a key regulator of lipid metabolism, as a ...

As investors and industry alike try to read the tea leaves of what the upcoming change in administrations holds for the U.S., speculation abounds about what Trump 2.0 will mean for the biopharma and ...